HK$8.89
9.15%
Hong Kong, Sep 18, 03:51 pm HKT. Closed.
Why the stock moved Why the stock moved Beta
ISIN
KYG0520K1094
Symbol
1672

Ascletis Pharma Inc Stock price

HK$8.97
-1.03 10.30% 1M
-5.81 39.31% 6M
-2.42 21.25% YTD
-1.53 14.57% 1Y
+7.08 374.60% 3Y
+6.23 227.37% 5Y
-5.03 35.93% 10Y
-5.03 35.93% 20Y
Hong Kong, Closing price Fri, Sep 18 2026
+0.83 10.13%
ISIN
KYG0520K1094
Symbol
1672
Industry

Is Ascletis Pharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,134 stocks worldwide.

Key metrics

Basic
Market capitalization
HK$8.7b
Enterprise Value
HK$6.4b
Net debt
positive
Cash
HK$2.2b
Shares outstanding
991.9m
Valuation (TTM | estimate)
P/E
negative
P/S
3,653.0 | 449.8
EV/Sales
2,717.3 | 334.6
EV/FCF
-
P/B
3.8
Financial Health
Equity Ratio
93.6%
Return on Equity
-18.6%
ROCE
-23.0%
ROIC
-350.7%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
HK$2.4m | HK$19.2m
EBITDA
-
EBIT
HK$-522.5m
Net Income
HK$-421.0m
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
58.0% | 712.1%
EBITDA
-
EBIT
-13.3%
Net Income
-19.6%
Free Cash Flow
-
Margin
Gross
26.0%
EBITDA
-
EBIT
-22,023.1%
Net
-17,745.6%
Free Cash Flow
-
More
EPS
HK$-0.4
FCF per Share
-
Short interest
-
Employees
202
Rev per Employee
HK$10.0k

Ascletis Pharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Ascletis Pharma Inc forecast:

7x Buy
78%
2x Hold
22%

Analyst Opinions

9 Analysts have issued a Ascletis Pharma Inc forecast:

Buy
78%
Hold
22%

Financial data from Ascletis Pharma Inc

Dec '25
+/-
%
2.37 2.37
58% 58%
100%
- Direct Costs 1.76 1.76
175% 175%
74%
0.62 0.62
28% 28%
26%
- Selling and Administrative Expenses 88 88
26% 26%
3,714%
- Research and Development Expense 479 479
35% 35%
20,190%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -522 -522
13% 13%
-22,045%
Net Profit -421 -421
20% 20%
-17,763%

In millions HKD.

Don't miss a Thing! We will send you all news about Ascletis Pharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Ascletis Pharma, Inc. engages in the research and development, production, marketing, and sale of pharmaceutical products. The firm focuses on viral diseases, non-alcoholic steatohepatitis (NASH) or primary biliary cholangitis (PBC), and oncology. The firm's product pipeline includes ASC22 for chronic hepatitis B functional cure, ASC10 for respiratory syncytial virus (RSV), ASC22 for human immunodeficiency virus (HIV) functional cure, ASC10 and ASC11 for COVID-19, ASC41 for NASH, ASC42 for PBC, ASC61 for solid tumors, ASC40 for moderate and severe acne, and others. The firm conducts its business in the domestic and overseas markets.

Head office Cayman Islands
CEO Dr. Wu
Employees 202
Website www.ascletis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today